Navigation Links
Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/28/2009

and Patient Instructions for Use.

About Trabectedin

Trabectedin is a novel cytotoxic antitumor agent that was originally derived from the Caribbean tunicate, Ecteinascidia turbinate ("sea squirt"). The compound is now produced synthetically. Trabectedin binds to the minor groove of DNA, interfering with cell division and genetic transcription processes and DNA repair machinery. Trabectedin is currently in Phase 3 development in ovarian cancer and to expand its uses in sarcoma.

According to the licensing agreement, PharmaMar SAU has rights to market the compound in Europe and Japan, while Centocor Ortho Biotech Products, L.P. has marketing rights for the product in the rest of the world.

About Centocor Ortho Biotech Products, L.P.

Centocor Ortho Biotech redefines the standard of care in immunology, nephrology, and oncology. The company was formed when Centocor, Inc. and Ortho Biotech Products, L.P. were consolidated in late 2008, and was renamed Centocor Ortho Biotech. Built upon a pioneering history, Centocor Ortho Biotech harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care.

Note: This release corresponds to ASCO abstracts 5526, 5550, 5551, 8591 and 9625


'/>"/>
SOURCE Centocor Ortho Biotech Products, L.P.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
3. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
4. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
6. GeneNews provides Centocor access to its osteoarthritis program
7. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
8. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
9. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
10. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
11. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... PARSIPPANY, N.J. , Aug. 31, 2014 ... New Drug Discovery program in Anti-Infective research when two ... the coveted Qualified Infectious Disease Product (QIDP) status from ... granted to drugs which act against pathogens which have ... and are identified by Centre for Disease Control (a ...
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... 29, 2014 Intrinsic Imaging, an ... GAMP® 5 compliant imaging core lab, announced today ... II clinical trial to assess a new treatment ... trial, Intrinsic Imaging will provide comprehensive imaging core ... and charter development, site qualification, site training and ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... (Nasdaq: SGMO ) announced today that Philip Gregory, ... on the progress of,Sangamo,s ZFP Therapeutic development programs and ... on Wednesday, October 10, 2007,at the BIO InvestorForum in ... and may be accessed via a link on,the Sangamo ...
... Thompson, President,and CEO of Oncolytics Biotech Inc. (TSX: ... the Company at the 15th annual BioPartnering Europe,conference ... 9 a.m. The conference,will be held at the ... About Oncolytics Biotech Inc. Oncolytics is ...
... (Nasdaq: MSHL ) will present at the BIO ... Thursday, October 11, 2007 at 12:00 pm. About ... MSHL ) is a specialist oncology company,focused on the ... flavonoid technology platform which has generated a,number of novel ...
Cached Biology Technology:Sangamo BioSciences to Present at the 2007 BIO InvestorForum 2Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe 2Marshall Edwards, Inc. to Present at BIO Investor Forum 2007 2Marshall Edwards, Inc. to Present at BIO Investor Forum 2007 3
(Date:9/2/2014)... in stride; others are done in by it. New ... of this so-called stress gap in mice with very ... researchers to better understand the development of psychiatric disorders ... animal has unique experiences as it goes through its ... alter the expression of genes, and as a result, ...
(Date:9/1/2014)... diet showed some modest improvement in the last decade ... consumption of unhealthy trans fats, but the gap in ... poor. , , An unhealthy diet is closely linked ... healthy diet is an important part of the strategy ... diet quality is important because it can offer guidance ...
(Date:9/1/2014)... It may be possible to train the brain to ... to new research by scientists at the Jean Mayer ... at Tufts University and at Massachusetts General Hospital. Published ... , a brain scan study in adult men and ... addictive power of unhealthy food while also increasing preference ...
Breaking Biology News(10 mins):Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3Training your brain to prefer healthy foods 2
... think a city would provide a good home for bats ... buildings. But researchers at the University of Calgary made the ... for these animals. "I was really surprised," says Dr. ... biological sciences at the University of Calgary and lead author ...
... CHAMPAIGN, lll. Blood clotting is a complicated business, ... to injury. In a new study, researchers report that they ... interaction that is vital to blood clotting. This interaction ... baffled scientists for decades. The study appears ...
... State University shows that so-called biodegradable products are likely ... are releasing a powerful greenhouse gas as they break ... utensils, are broken down in landfills by microorganisms that ... a paper describing the research and professor and head ...
Cached Biology News:Big city holds empty promise for bats 2Team solves decades-old molecular mystery linked to blood clotting 2Team solves decades-old molecular mystery linked to blood clotting 3Study: Biodegradable products may be bad for the environment 2
... , Maintenance 112 days/each ... , Immunizations/Boost injections x5 /each ... , Production bleed (25 ml blood ... ~ 100 ml blood (~50 ml serum) x1 each ...
chk 1 kinase...
... Cell Functional Identification Kit contains specially ... used for the short-term maintenance, differentiation, ... induction of NSCs into astrocyte, neuron ... consisting of mouse anti-human Nestin, mouse ...
Rat Antibody to Kinase Suppressor Of Ras Recognises the kinase suppressor of Ras (KSR). Immunogen: Recombinant human KSR protein Specificity: human kinase supressor of Ras...
Biology Products: